It is being developed by Eli Lilly and Company and is currently in Phase 3 clinical trials (registered on ClinicalTrials.gov)
[PMID: 10828840] PubMed record related to this compound for laboratory literature review
Formulated with Glutathione, Vitamin C, Niacinamide, and Alpha Arbutin, it reduces dark spots, evens out skin tone, and minimizes the appearance of wrinkles
For example, some people find the side effects intolerable
After stopping, appetite typically returns gradually over days to weeks, and some people may experience increased hunger compared to when they were on treatment
Dosage schedules vary depending on concentration and formulation